212 related articles for article (PubMed ID: 34369074)
1. Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report.
Kawakado K; Tamura T; Nakanishi M; Makimoto G; Sato Y; Kuyama S
Thorac Cancer; 2021 Sep; 12(18):2513-2516. PubMed ID: 34369074
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab.
Ninomiya R; Kinehara Y; Tobita S; Konaka H; Jokoji R; Shintani T; Tachibana I
Intern Med; 2022 Aug; 61(15):2339-2341. PubMed ID: 35022350
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
4. First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature.
Zhang C; Kong FW; Wu WB; Zhang M; Yu GM; Wang X; Liu YY
Medicine (Baltimore); 2020 Sep; 99(36):e22128. PubMed ID: 32899099
[TBL] [Abstract][Full Text] [Related]
5. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
6. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Velcheti V; Hu X; Piperdi B; Burke T
Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
Awad MM; Gadgeel SM; Borghaei H; Patnaik A; Yang JC; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Altan M; Jalal SI; Panwalkar A; Gubens M; Sequist LV; Saraf S; Zhao B; Piperdi B; Langer CJ
J Thorac Oncol; 2021 Jan; 16(1):162-168. PubMed ID: 33069888
[TBL] [Abstract][Full Text] [Related]
9. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Rong Han S; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2021 Dec; 112(12):5000-5010. PubMed ID: 34543477
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
Kodali S; Tipirneni E; Gibson PC; Cook D; Verschraegen C; Lane KA
Ophthalmic Plast Reconstr Surg; 2018; 34(5):e149-e151. PubMed ID: 29979269
[TBL] [Abstract][Full Text] [Related]
12. [A case of Carboplatin and pemetrexed combination chemotherapy for synchronous double cancers of hepatocellular carcinoma and primary lung cancer].
Okamoto E; Sato J; Sema M; Hayasaka J; Watanabe A; Takagi K; Kusano-Kitazume A; Tamura A; Kondo M; Sakuranaka H; Ochi J; Hanada S; Tanaka M; Akita H; Tei S; Ichioka M; Shibayama T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2154-6. PubMed ID: 25731454
[TBL] [Abstract][Full Text] [Related]
13. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival with maintenance pemetrexed for a multiple primary malignancy.
Shuayb M; Reza MS
BMJ Support Palliat Care; 2019 Mar; 9(1):51-53. PubMed ID: 29776903
[TBL] [Abstract][Full Text] [Related]
15. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
[TBL] [Abstract][Full Text] [Related]
16. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
[TBL] [Abstract][Full Text] [Related]
17. Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer.
Hashimoto K; Kaira K; Kawasaki T; Yamaguchi O; Kagamu H
Lung Cancer; 2020 Jan; 139():221-223. PubMed ID: 31806361
[No Abstract] [Full Text] [Related]
18. Acute myocarditis during carboplatin and pemetrexed chemotherapy for lung adenocarcinoma.
Yangui F; Zaiem A; Antit S; Bellakhal S; Zakhama L; Charfi MR
Therapie; 2021; 76(5):486-488. PubMed ID: 32654796
[No Abstract] [Full Text] [Related]
19. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.
Nakano Y; Koide N; Koyama Y; Nitta K; Koizumi T
Thorac Cancer; 2021 Feb; 12(4):557-559. PubMed ID: 33350050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
